Health Canada revised the labeling for cholesterol-lowering statins to warn consumers about potential risk of developing type 2 diabetes. The change came 11 months after the FDA made a similar move in the U.S. Health Canada's slow action was criticized by drug safety researcher Dr. David Juurlink, who said "Canadians have a right to wonder why the agency tasked with protecting their health should act so much more slowly than its U.S. counterpart."

Full Story:
CTV.ca (Canada)

Related Summaries